These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10771447)

  • 1. Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics.
    Tandon R
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):1S-3S. PubMed ID: 10771447
    [No Abstract]   [Full Text] [Related]  

  • 2. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.
    Stip E; Zhornitsky S; Moteshafi H; Létourneau G; Stikarovska I; Potvin S; Tourjman V
    Clin Ther; 2011 Dec; 33(12):1853-67. PubMed ID: 22133697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An African patient with ziprasidone intolerance.
    Hein J; Gregor A; Bartholomä A; Heinz A; Juckel G
    J Clin Psychiatry; 2005 Jun; 66(6):800. PubMed ID: 15960579
    [No Abstract]   [Full Text] [Related]  

  • 5. Applying parsimony to "An African patient with ziprasidone intolerance".
    Anders JL
    J Clin Psychiatry; 2005 Nov; 66(11):1491; author reply 1491-2. PubMed ID: 16420091
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
    Preskorn SH
    Clin Pharmacokinet; 2005; 44(11):1117-33. PubMed ID: 16231965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsades de pointes associated with ziprasidone.
    Heinrich TW; Biblo LA; Schneider J
    Psychosomatics; 2006; 47(3):264-8. PubMed ID: 16684946
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Drug Investig; 2014 Oct; 34(10):691-9. PubMed ID: 25047407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
    Kelly DL; Love RC
    Psychopharmacol Bull; 2001; 35(4):66-79. PubMed ID: 12397857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism update for some recent antipsychotics.
    Caccia S
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):829-46. PubMed ID: 21476873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.
    Miceli JJ; Smith M; Robarge L; Morse T; Laurent A
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):71S-76S. PubMed ID: 10771458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
    Mandrioli R; Protti M; Mercolini L
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):149-74. PubMed ID: 25483358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
    Miceli JJ; Wilner KD; Hansen RA; Johnson AC; Apseloff G; Gerber N
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):5S-13S. PubMed ID: 10771448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of food on the absorption of oral ziprasidone.
    Miceli JJ; Glue P; Alderman J; Wilner K
    Psychopharmacol Bull; 2007; 40(3):58-68. PubMed ID: 18007569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder.
    Cañas F; Correll CU; Fagiolini A; Larmo I; Levy P; Papageorgiou G; Rossi A; Zink M; Montes JM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2245-63. PubMed ID: 21801083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.